Lupin rallies on USFDA approval for generic drug

Short resume:

lupin
90%
economic
70%
times
50%
displayedwill
40%
Lupin rallies on USFDA approval for generic drug

NEW DELHI: Shares of Lupin rallied nearly 2 per cent in the morning trade on Wednesday after Lupin Pharmaceuticals (LPI), the US subsidiary of Indian drug maker, received the US Food and Drug Administration’s (FDA) approval for its armodafinil tablets.
Source Economic Times
Read More…

More News


Be the first to comment

Leave a Reply

Your email address will not be published.


*